Table 1. Fusion Point-Specific... | American Society of Hematology

Table 1.

Fusion Point-Specific Inhibition of Clonogenic Growth of Primary Cells From Three Patients With CML bybcr-abl–Directed Antisense ODN

Phase of Disease	Fusion Point	Colony No. as Percentage of Untreated Control
Phase of Disease	Fusion Point	DOTAP	Antisense b3a2	Scrambled b3a2	Antisense b2a2	Scrambled b2a2
CP	b3a2	90/83	49/61	83/78	85/95	83/83
CP	b2a2	123/128	104/107	95/97	28/35	102/104
AP	b2a2	109/85	117/120	117/99	61/52	129/88

Phase of Disease	Fusion Point	Colony No. as Percentage of Untreated Control
Phase of Disease	Fusion Point	DOTAP	Antisense b3a2	Scrambled b3a2	Antisense b2a2	Scrambled b2a2
CP	b3a2	90/83	49/61	83/78	85/95	83/83
CP	b2a2	123/128	104/107	95/97	28/35	102/104
AP	b2a2	109/85	117/120	117/99	61/52	129/88

Mononuclear blood cells were seeded in semisolid growth medium after double transfection of ODN (concentrations in first and second transfection: 1 μmol/L and 0.5 μmol/L, respectively) by DOTAP. The mean value of colony numbers (CFU-GM, BFU-E) after 2 weeks compared with untreated controls are indicated. Significant reduction of colony numbers is marked by bold letters.

Abbreviations: CP, chronic phase; AP, accelerated phase.

View Large

This Feature Is Available To Subscribers Only